🌳 Justice, finally?
Shou el akhbar. Lebanon is juggling a lot this Tuesday: a landmark port blast verdict is inching closer, cancer patients are fighting wars on multiple fronts, and Hezbollah is demanding the government cancel direct talks with Israel—set for today in Washington. Let's get into it.
TOP STORIES
Beirut Port Blast Judge Hands Over Files—Indictment Expected in July
The backstory: On August 4, 2020, a massive explosion at Beirut's port killed over 200 people and devastated the city. Judge Tarek Bitar has been leading the investigation for nearly six years, repeatedly blocked by politicians and security officials seeking immunity from prosecution.
- Judge Bitar has transferred his full investigation files to Prosecutor Mohammad Saab, after a coordinating meeting with the general prosecution—marking the final stretch before an indictment is issued.
- The indictment targets 70 defendants—politicians, security officials, and judges—and is expected to land in July, just before the sixth anniversary of the blast on August 4.
- Outgoing Cassation Prosecutor Jamal Hajjar, who retires on April 25 after just 9 remaining working days, had publicly vowed to clear the path for Bitar before leaving office—a promise only partially fulfilled.
- The timing is politically charged: Lebanon is simultaneously entering direct negotiations with Israel and attempting to assert state authority over non-state armed groups.
What to watch: Whether the incoming Cassation Prosecutor supports or stalls Bitar's indictment will determine if Lebanon finally delivers accountability—or kicks the can six more years down the road.
Hezbollah's Kassem Tells Beirut to Walk Away From Washington Talks—As Bint Jbeil Burns
- Hezbollah leader Naim Kassem called on Lebanon's government Monday to cancel Tuesday's direct talks with Israel in Washington, the first such face-to-face meeting in decades, calling it a "free concession" to Israel and the U.S.
- Lebanon's position frames the talks as a path to ceasefire; Israel has framed them as peace negotiations requiring Hezbollah disarmament, with no withdrawal from southern Lebanon discussed.
- At least 2,055 people have been killed in Israeli strikes in Lebanon, including 252 women, 165 children, and 87 medical workers, while not reported others were wounded and more than 1 million displaced from the 2024 war, according to Lebanon's Health Ministry.
- Fierce fighting continued in Bint Jbeil on Monday, with Israel saying its forces killed more than 100 Hezbollah fighters and destroyed the stadium where Nasrallah famously gave his 2000 victory speech.
Zooming out: Kassem's public pressure on the Lebanese government—combined with ongoing ground fighting in the south—reveals the fundamental contradiction at the heart of any ceasefire deal: Lebanon's state and Hezbollah do not share the same endgame.
$5,400 a Session: How Lebanon's Cancer Patients Are Fighting Two Wars at Once
- A major investigative report by Daraj and the ICIJ reveals that Lebanon recorded 16,226 new cancer cases in 2024, with infection rates rising 162% between 1990 and 2023—making it one of the fastest-rising cancer rates in the world, per The Lancet.
- Keytruda, a leading immunotherapy drug, costs roughly $2,700 per dose—patients typically need two doses every three weeks, adding up to more than $5,000 a month, far beyond reach without state or insurance coverage.
- During the peak of Lebanon's economic crisis in 2021, the country went nearly 5 months without any imported medications; patients unable to afford black-market prices—sometimes up to $9,000 for two doses—simply stopped treatment.
- A digitization push under former Health Minister Firas Abiad raised the share of eligible patients actually receiving the drug from 20% to over 90%, and cut cancer drug costs by 45–50% through unified government procurement.
The bigger picture: Lebanon's cancer crisis—underfunded, disrupted by war, and priced out of reach for most families—exposes how a collapsing healthcare system turns a medical diagnosis into a financial death sentence.
QUICK HITS
- Hezbollah's red line: Senior Hezbollah official Wafiq Safa told AP on Monday that the group will not be bound by any outcomes from the Lebanon-Israel Washington talks, adding that all communications with the Lebanese government currently run exclusively through Parliament Speaker Nabih Berri.
- 490 schools, still occupied: More than 367,000 displaced children remain outside stable learning environments, with 490 schools still functioning as shelters; only 608 public schools have reopened for in-person classes, reaching just 142,222 students so far.
- Teachers draw a red line: Lebanon's public school teachers union is threatening to boycott official national exams unless the government disburses six previously approved salary raises and extends full contracts to war-displaced teaching staff through the end of the academic year.
- The south's vanishing harvest: Over 70% of southern Lebanon's 17,000 farmers have fled, and Israeli operations have damaged more than 490 million square meters—roughly 22% of Lebanon's total agricultural land—with olive and citrus groves bearing the worst of it.
- Dust and heat incoming: Lebanon's meteorological authority is forecasting a sharp temperature spike reaching 30°C on the coast by Thursday, accompanied by desert dust clouds and winds gusting up to 60 km/h—well above April's seasonal norms.
INTERNATIONAL
Keytruda's $163 Billion Divide: How One Drug Became the World's Most Unequal Treatment
- A yearlong investigation by the ICIJ and 124 journalists across 37 countries found that Merck's cancer drug Keytruda generated $31.7 billion in sales in 2025 alone—nearly half the company's total revenue—while remaining unaffordable for most of the world's cancer patients.
- Annual treatment costs range from roughly $80,000 in Germany to $208,000 in the United States; a patient earning a median income in South Africa cannot afford even a single dose in a year, per Deutsche Welle.
- Merck has filed at least 1,212 patent applications across 53 jurisdictions, with 211 already granted patents potentially extending market exclusivity until at least 2042—a full 14 years past the original patent expiry in 2028.
- Since launch, Merck has directed roughly $75 billion in dividends to shareholders and $43 billion in share buybacks, while a Swiss nonprofit estimates actual R&D costs at just $1.9 billion—about 1% of global revenues.
The bigger picture: Keytruda's global price disparities—with Lebanon's annual cost sitting at $93,000, per Daraj and the ICIJ—illustrate how patent systems and opaque pricing determine survival odds based on geography and income rather than medical need.
Lafarge Convicted: French Cement Giant Fined, Former CEO Jailed for Funding ISIS in Syria
- A Paris court on Monday found cement group Lafarge—now part of Swiss conglomerate Holcim—guilty of financing terrorism, ruling that its Syrian subsidiary paid 5.59 million euros to armed groups including ISIS and the al-Nusra Front between 2013 and 2014 to keep its northern Syria plant operational.
- Former CEO Bruno Lafont was sentenced to six years in prison and ordered to begin serving immediately; seven other former executives received sentences ranging from fines to seven years in jail, according to Al Jazeera.
- The court ordered Lafarge to pay a fine of 1.12 million euros and forfeit 30 million euros in assets; Lafont's lawyer has said he plans to appeal, per The Guardian.
Zooming out: The verdict marks the first time a company has been convicted in France for financing terrorism, setting a precedent for corporate accountability in conflict zones that legal experts say could reshape how multinationals assess operational risk in war-torn countries.
Australia Appoints Its First Female Army Chief in 125-Year Military History
- Australia announced Monday that Lieutenant General Susan Coyle, 55, will become the country's first female army chief in its 125-year military history, taking command in July and replacing Lieutenant General Simon Stuart, according to The Independent.
- Coyle, a three-decade veteran who served in Afghanistan, the Solomon Islands, and the Middle East, currently heads joint capabilities overseeing space and cyber domains; she graduated from Australia's Defence Force Academy in 1992.
- Women currently make up around 21% of Australia's Defence Force and 18.5% of senior leadership roles, with a target of 25% overall female participation set for 2030—amid an ongoing class action lawsuit filed last October alleging systematic sexual harassment across the military.
What to watch: Coyle's appointment arrives as Australia undergoes a major military transformation—equipping its forces with long-range weapons, drones, and modern combat tools—making the incoming chief's background in cyber and space warfare particularly significant.
GHER HEK
- Art as the antidote: Beirut-born artist Abed Al Kadiri has held drawing sessions in six institutions across Lebanon, inviting displaced children to fill long rolls of paper with their dreams and memories—over 300 children involved so far, with a goal of reaching 1,000, and future exhibitions planned to benefit their families.
- Oasis is finally in: The Rock & Roll Hall of Fame announced its Class of 2026 on Monday, inducting Oasis, Wu-Tang Clan, Sade, Iron Maiden, Phil Collins, Billy Idol, Joy Division/New Order, and Luther Vandross—with the '80s officially crowned as the Hall's decade of choice.
- History in the dugout: Marie-Louise Eta, 34, became the first woman ever to manage a men's team in one of Europe's top five football leagues, taking interim charge of Union Berlin in the Bundesliga—a milestone hailed by England women's coach Sarina Wiegman as the work of a "trailblazer."
- Miles is back: Sony dropped first footage of Spider-Man: Beyond the Spider-Verse at CinemaCon, with directors calling it the most emotional chapter yet and the "final" installment of Miles Morales' trilogy—swinging into theaters on June 18, 2027.
Thanks for reading—see you tomorrow.